1196 related articles for article (PubMed ID: 24965850)
1. Performance of (18)F-FDG PET/CT as a postoperative surveillance imaging modality for asymptomatic advanced gastric cancer patients.
Lee DY; Lee CH; Seo MJ; Lee SH; Ryu JS; Lee JJ
Ann Nucl Med; 2014 Oct; 28(8):789-95. PubMed ID: 24965850
[TBL] [Abstract][Full Text] [Related]
2. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic performance of FDG PET/CT for surveillance in asymptomatic gastric cancer patients after curative surgical resection.
Lee JW; Lee SM; Son MW; Lee MS
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):881-888. PubMed ID: 26611426
[TBL] [Abstract][Full Text] [Related]
4. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
5. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
6. Detecting recurrence of gastric cancer: the value of FDG PET/CT.
Park MJ; Lee WJ; Lim HK; Park KW; Choi JY; Kim BT
Abdom Imaging; 2009 Jul; 34(4):441-7. PubMed ID: 18543017
[TBL] [Abstract][Full Text] [Related]
7. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma.
Park JW; Jo MK; Lee HM
BJU Int; 2009 Mar; 103(5):615-9. PubMed ID: 19007371
[TBL] [Abstract][Full Text] [Related]
8. Primary Tumor ¹⁸F-FDG Avidity Affects the Performance of ¹⁸F-FDG PET/CT for Detecting Gastric Cancer Recurrence.
Kim SJ; Cho YS; Moon SH; Bae JM; Kim S; Choe YS; Kim BT; Lee KH
J Nucl Med; 2016 Apr; 57(4):544-50. PubMed ID: 26678615
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of FDG-PET/CT at the postoperative surveillance in the breast cancer patients.
Jung NY; Yoo IR; Kang BJ; Kim SH; Chae BJ; Seo YY
Breast Cancer; 2016 Jan; 23(1):141-148. PubMed ID: 24872087
[TBL] [Abstract][Full Text] [Related]
10. Role of FDG-PET/CT in follow-up of patients treated with resective gastric surgery for tumour.
Graziosi L; Bugiantella W; Cavazzoni E; Cantarella F; Porcari M; Baffa N; Donini A
Ann Ital Chir; 2011; 82(2):125-9. PubMed ID: 21682102
[TBL] [Abstract][Full Text] [Related]
11. The role of 18F-FDG PET/CT in the evaluation of gastric cancer recurrence after curative gastrectomy.
Lee JE; Hong SP; Ahn DH; Jeon TJ; Kang MK; Kwon CI; Ko KH; Hwang SG; Park PW; Rim KS
Yonsei Med J; 2011 Jan; 52(1):81-8. PubMed ID: 21155039
[TBL] [Abstract][Full Text] [Related]
12. A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer.
Smyth E; Schöder H; Strong VE; Capanu M; Kelsen DP; Coit DG; Shah MA
Cancer; 2012 Nov; 118(22):5481-8. PubMed ID: 22549558
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis of metastases from postoperative differentiated thyroid cancer: comparison between FDG and FLT PET/CT studies.
Nakajo M; Nakajo M; Jinguji M; Tani A; Kajiya Y; Tanabe H; Fukukura Y; Nakabeppu Y; Koriyama C
Radiology; 2013 Jun; 267(3):891-901. PubMed ID: 23468571
[TBL] [Abstract][Full Text] [Related]
14. Clinical role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in post-operative follow up of gastric cancer: initial results.
Sun L; Su XH; Guan YS; Pan WM; Luo ZM; Wei JH; Wu H
World J Gastroenterol; 2008 Aug; 14(29):4627-32. PubMed ID: 18698676
[TBL] [Abstract][Full Text] [Related]
15. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
[TBL] [Abstract][Full Text] [Related]
16. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
Jadvar H; Henderson RW; Conti PS
J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
[TBL] [Abstract][Full Text] [Related]
17. Utility of (18)F-FDG PET-CT in staging and restaging of patients with malignant salivary gland tumours: a single-institutional experience.
Sharma P; Jain TK; Singh H; Suman SK; Faizi NA; Kumar R; Bal C; Malhotra A; Kumar R
Nucl Med Commun; 2013 Mar; 34(3):211-9. PubMed ID: 23353886
[TBL] [Abstract][Full Text] [Related]
18. Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT.
Yun M; Lim JS; Noh SH; Hyung WJ; Cheong JH; Bong JK; Cho A; Lee JD
J Nucl Med; 2005 Oct; 46(10):1582-8. PubMed ID: 16204706
[TBL] [Abstract][Full Text] [Related]
19. [Clinical application of (18)F-FDG PET/CT to staging and treatment effectiveness monitoring of nasopharyngeal carcinoma].
Wang GH; Lau EW; Shakher R; Binns DS; Hogg A; Drummond E; Hicks RJ
Ai Zheng; 2007 Jun; 26(6):638-42. PubMed ID: 17562272
[TBL] [Abstract][Full Text] [Related]
20. The clinical value of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in postoperative patients with gastrointestinal mucinous adenocarcinoma.
Yang ZY; Hu SL; Shi W; Zhu BL; Xu JY; Zhang YJ
Nucl Med Commun; 2011 Nov; 32(11):1018-25. PubMed ID: 21956489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]